Targeting this axis, by inducing RKIP or inhibiting YY1, should result in the inhibition of tumor growth and metastases as well as restoring cancer cells’ response to chemotherapeutic and immunotherapeutic interventions. The gene discussed is PEBP1; the disease is neoplasm.